Autogenous Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Autogenous Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The global autogenous vaccines market is on a growth trajectory, with worldwide revenue reaching US$ 140 million in 2024. According to a recent analysis report, the market is projected reach US$ 220 million by the end of 2031. The rising demand for autogenous vaccines in livestock management and the creation of customized vaccines are key drivers of this growth.

Factors Driving the Autogenous Vaccines Market

Managing Livestock and Disease Control: The market is being driven by the need for improved animal health and welfare in livestock management. With a focus on reducing the use of antibiotics in animal husbandry, autogenous vaccines play a vital role in disease management. The limited availability of veterinary medicines for some species has led to the use of accessible products for treating affected animals.

Customized Autogenous Vaccines: Manufacturers are developing custom autogenous vaccines, especially in poultry farming, to address evolving and specific serotypes of diseases. These customized vaccines are farm-specific and provide a close match to the field's changing environment, ensuring better protection against infectious diseases.

Direct Customer Interactions: Companies in the animal healthcare products sector, particularly those serving poultry farmers, are establishing direct customer relationships to promote awareness, disease management, treatment protocols, and training. These efforts enhance customer trust and improve the effectiveness of products.

Challenges Impacting the Global Autogenous Vaccines Market

Gaps in Epidemiological Knowledge: Limited knowledge about the epidemiology of veterinary diseases, particularly in endemic regions, creates challenges for disease control. For example, the absence of adequate epidemiological knowledge regarding diseases like Newcastle Disease in poultry hampers vaccine development and disease prevention.

Stringent Regulatory Framework: Regulatory requirements for the development and distribution of autogenous vaccines vary from country to country. Some nations lack uniform regulations for autogenous vaccines, leading to delays in approvals and distribution.

Country-wise Insights

U.S. Autogenous Vaccines Market

The U.S. plays a significant role in the global autogenous vaccines market. Government initiatives and programs, such as those by the USDA, support awareness campaigns and research to develop customized vaccines for livestock.

Germany Autogenous Vaccines Market

Germany dominates the European market due to favorable regulatory conditions, increased awareness of animal health, and robust public funding for research and development of new vaccines. Improved product accessibility across the country also contributes to its leadership in the regional market.

Japan Autogenous Vaccines Market

The Japanese market is emerging as a prominent player, driven by growing livestock industries and increased efforts by manufacturers to engage with end-users directly. Rising financing and support for international veterinary disease eradication initiatives and the popularity of animal health insurance are expected to boost vaccine demand.

Competitive Landscape

The autogenous vaccines market features both global and regional players. Leading companies are focusing on inorganic expansions and mergers and acquisitions to maintain market competitiveness. Key players in the market include,
• Newport Laboratories, Inc.
• Elanco Animal Health
• Ceva (Ceva Biovac)
• ACE Laboratory Services (Apiam Animal Health)
• Huvepharma, Inc.
• AniCon Labor GmbH
• Cambridge Technologies
• Dyntec s. r. o
• Hygieia Biological Laboratories
• HIPRA
• Vaxxinova
• sanphar (ipeve)
• Addison Biological Laboratory
• Zoetis (PHARMAQ AS)
• Barramundi Asia Pte Ltd.(UVAXX Asia)
• Kennebec River Biosciences

Key Segments Covered in Autogenous Vaccines Industry Research

Product:
• Bacterial Strain
• Virus Strain

End User:
• Veterinary Research Institutes
• Livestock Farming Companies
• Veterinary Clinics and Hospitals

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa



Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global Autogenous Vaccines Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Autogenous Vaccines Market Outlook, 2018 – 2031
3.1. Global Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Bacterial Strain
3.1.1.2. Virus Strain
3.2. Global Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. Veterinary Research Institutes
3.2.1.2. Livestock Farming Companies
3.2.1.3. Veterinary Clinics and Hospitals
3.3. Global Autogenous Vaccines Market Outlook, by Region, Value (US$ Mn), 2018 – 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Autogenous Vaccines Market Outlook, 2018 – 2031
4.1. North America Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Bacterial Strain
4.1.1.2. Virus Strain
4.2. North America Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. Veterinary Research Institutes
4.2.1.2. Livestock Farming Companies
4.2.1.3. Veterinary Clinics and Hospitals
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Autogenous Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
4.3.1.2. U.S. Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
4.3.1.3. Canada Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
4.3.1.4. Canada Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Autogenous Vaccines Market Outlook, 2018 – 2031
5.1. Europe Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Bacterial Strain
5.1.1.2. Virus Strain
5.2. Europe Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Veterinary Research Institutes
5.2.1.2. Livestock Farming Companies
5.2.1.3. Veterinary Clinics and Hospitals
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Autogenous Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
5.3.1. Key Highlights
5.3.1.1. Germany Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.2. Germany Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.3. U.K. Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.4. U.K. Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.5. France Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.6. France Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.7. Italy Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.8. Italy Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.9. Turkey Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.10. Turkey Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.11. Russia Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.12. Russia Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.1.13. Rest of Europe Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
5.3.1.14. Rest of Europe Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Autogenous Vaccines Market Outlook, 2018 – 2031
6.1. Asia Pacific Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Bacterial Strain
6.1.1.2. Virus Strain
6.2. Asia Pacific Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. Veterinary Research Institutes
6.2.1.2. Livestock Farming Companies
6.2.1.3. Veterinary Clinics and Hospitals
6.2.2. Others BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Autogenous Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
6.3.1. Key Highlights
6.3.1.1. China Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.2. China Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.1.3. Japan Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.4. Japan Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.1.5. South Korea Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.6. South Korea Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.1.7. India Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.8. India Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.1.9. Southeast Asia Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.10. Southeast Asia Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.1.11. Rest of Asia Pacific Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
6.3.1.12. Rest of Asia Pacific Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Autogenous Vaccines Market Outlook, 2018 – 2031
7.1. Latin America Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Bacterial Strain
7.1.1.2. Virus Strain
7.2. Latin America Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
7.2.1.1. Veterinary Research Institutes
7.2.1.2. Livestock Farming Companies
7.2.1.3. Veterinary Clinics and Hospitals
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Autogenous Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
7.3.1.2. Brazil Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
7.3.1.3. Mexico Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
7.3.1.4. Mexico Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
7.3.1.5. Argentina Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
7.3.1.6. Argentina Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
7.3.1.7. Rest of Latin America Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
7.3.1.8. Rest of Latin America Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Autogenous Vaccines Market Outlook, 2018 – 2031
8.1. Middle East & Africa Autogenous Vaccines Market Outlook, by Product, Value (US$ Mn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Bacterial Strain
8.1.1.2. Virus Strain
8.2. Middle East & Africa Autogenous Vaccines Market Outlook, by End User, Value (US$ Mn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. Veterinary Research Institutes
8.2.1.2. Livestock Farming Companies
8.2.1.3. Veterinary Clinics and Hospitals
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Autogenous Vaccines Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
8.3.1. Key Highlights
8.3.1.1. GCC Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
8.3.1.2. GCC Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
8.3.1.3. South Africa Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
8.3.1.4. South Africa Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
8.3.1.5. Egypt Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
8.3.1.6. Egypt Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
8.3.1.7. Nigeria Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
8.3.1.8. Nigeria Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
8.3.1.9. Rest of Middle East & Africa Autogenous Vaccines Market by Product, Value (US$ Mn), 2018 – 2031
8.3.1.10. Rest of Middle East & Africa Autogenous Vaccines Market by End User, Value (US$ Mn), 2018 – 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Newport Laboratories, Inc. (Boehringer Ingelheim International GmbH)
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Elanco Animal Health
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Phibro Animal Health Corporation
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Ceva Santé Animale
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. ACE Laboratory Services (Apiam Animal Health)
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Huvepharma, Inc.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. AniCon Labor GmbH
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Cambridge Technologies
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Dyntec s. r. o
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Hygieia Biological Laboratories
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. HIPRA
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Vaxxinova
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Sanphar (Ipeve)
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Addison Biological Laboratory
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Zoetis (PHARMAQ AS)
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. Barramundi Asia Pte Ltd. (UVAXX Asia)
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
9.4.17. Kennebec River Biosciences
9.4.17.1. Company Overview
9.4.17.2. Product Portfolio
9.4.17.3. Financial Overview
9.4.17.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings